Publicaciones en las que colabora con Domingo Francisco Javier Díez Martínez (178)

2024

  1. Circulating biomarkers of myocardial remodelling: current developments and clinical applications

    Heart, Vol. 110, Núm. 19, pp. 1157-1163

  2. Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial

    Hypertension Research

  3. Myocardial Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical Management

    Hypertension, Vol. 81, Núm. 2, pp. 218-228

  4. Myocardial fibrosis from the perspective of the extracellular matrix: Mechanisms to clinical impact

    Matrix Biology, Vol. 134, pp. 1-22

  5. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

    Heart, Vol. 110, Núm. 19, pp. 1180-1187

2023

  1. Cardiac Fibrosis in heart failure: Focus on non-invasive diagnosis and emerging therapeutic strategies

    Molecular Aspects of Medicine, Vol. 93

  2. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

    Circulation: Heart Failure, Vol. 16, Núm. 5, pp. E009694

  3. The Spanish Scientific Societies before the ESC 2021 guidelines on vascular disease prevention: Generalizing the measurement of albuminuria to identify vascular risk and prevent vascular disease

    Nefrologia, Vol. 43, Núm. 2, pp. 245-250

2022

  1. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

    Cancers, Vol. 14, Núm. 12

  2. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

  3. Heart failure in chronic kidney disease: The emerging role of myocardial fibrosis

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 5, pp. 817-824

2021

  1. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

    Nature Reviews Cardiology, Vol. 18, Núm. 7, pp. 479-498

  2. Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension

    JACC: Basic to Translational Science, Vol. 6, Núm. 1, pp. 12-21

2020

  1. Author Correction: MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure (Scientific Reports, (2017), 7, 1, (40696), 10.1038/srep40696)

    Scientific Reports

  2. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action

    Nefrologia, Vol. 40, Núm. 3, pp. 223-236

  3. Cardiac magnetic resonance-derived fibrosis, strain and molecular biomarkers of fibrosis in hypertensive heart disease

    Journal of hypertension, Vol. 38, Núm. 10, pp. 2036-2042

  4. Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 835-843

  5. Does chronic kidney disease facilitate malignant myocardial fibrosis in heart failure with preserved ejection fraction of hypertensive origin?

    Journal of Clinical Medicine, Vol. 9, Núm. 2

  6. Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers

    Open Heart, Vol. 7, Núm. 1

  7. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction

    Circulation, Vol. 141, Núm. 9, pp. 751-767